MA40737A - Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 - Google Patents

Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1

Info

Publication number
MA40737A
MA40737A MA040737A MA40737A MA40737A MA 40737 A MA40737 A MA 40737A MA 040737 A MA040737 A MA 040737A MA 40737 A MA40737 A MA 40737A MA 40737 A MA40737 A MA 40737A
Authority
MA
Morocco
Prior art keywords
determinants
immunotherapy
blocked
cancer response
cancer
Prior art date
Application number
MA040737A
Other languages
English (en)
Inventor
Timothy A Chan
Matthew D Hellman
Naiyer A Rizvi
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA40737A publication Critical patent/MA40737A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA040737A 2014-11-21 2015-11-22 Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 MA40737A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US201562132381P 2015-03-12 2015-03-12

Publications (1)

Publication Number Publication Date
MA40737A true MA40737A (fr) 2017-07-04

Family

ID=56014697

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040737A MA40737A (fr) 2014-11-21 2015-11-22 Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1

Country Status (8)

Country Link
US (3) US20180291074A1 (fr)
EP (2) EP3220950A4 (fr)
JP (4) JP7173733B2 (fr)
CN (2) CN107206064B (fr)
AU (3) AU2015349644B2 (fr)
HK (1) HK1244440A1 (fr)
MA (1) MA40737A (fr)
WO (1) WO2016081947A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
KR102833333B1 (ko) 2016-01-08 2025-07-11 니코데 테라퓨틱스 에이에스에이 치료적 항암 네오에피토프 백신
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
CN109196121B (zh) 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
KR102413032B1 (ko) * 2016-03-01 2022-06-24 노쓰 캐롤라이나 스테이트 유니버시티 마이크로니들 패치-보조된 전달에 의한 향상된 암 면역요법
MX2018009692A (es) * 2016-03-02 2018-12-19 Toray Industries Inductor de inmunidad.
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
WO2018039567A1 (fr) 2016-08-25 2018-03-01 Nantomics, Llc Marqueurs pour l'immunothérapie et leurs utilisations
EP3523451A1 (fr) 2016-10-06 2019-08-14 Genentech, Inc. Méthodes thérapeutiques et de diagnostic du cancer
EP3523450A1 (fr) * 2016-10-07 2019-08-14 Omniseq, Inc. Procédés et systèmes pour déterminer des thérapies personnalisées
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
CA3050109A1 (fr) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigenes et leurs utilisations dans le traitement du cancer
EP3576780A1 (fr) 2017-02-01 2019-12-11 Modernatx, Inc. Compositions thérapeutiques immunomodulatrices d'arnm codant pour des peptides de mutation d'activation d'oncogènes
WO2018145023A1 (fr) * 2017-02-06 2018-08-09 Novartis Ag Procédé de prédiction de la réponse à une immunothérapie
US20190360051A1 (en) * 2017-02-17 2019-11-28 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
BR112019019407A2 (pt) * 2017-03-20 2020-05-26 Genocea Biosciences Inc. Métodos de tratamento
WO2018183928A1 (fr) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Procédés de traitement de tumeur
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
EP3655034A1 (fr) * 2017-07-21 2020-05-27 Genentech, Inc. Procédés thérapeutiques et de diagnostic du cancer
WO2019023624A1 (fr) * 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Biomarqueur sanguin périphérique prédictif pour inhibiteurs de points de contrôle
CA3073531A1 (fr) * 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Polytherapie a base d'anticorps anti-csf1r et anti-pd -1 pour le cancer du pancreas
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
AU2018338441B2 (en) 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
CA3076918A1 (fr) * 2017-10-02 2019-04-11 Curematch, Inc. Procede de prediction de l'antigenicite et/ou de l'immunogenicite d'un neo-peptide derive d'une tumeur, a l'aide de motifs de signature mutationnelle
WO2019075112A1 (fr) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Identification de néo-antigènes au moyen de points chauds
CN111213209A (zh) 2017-10-12 2020-05-29 南托米克斯有限责任公司 根据生物体液的评估用癌症评分和反应预测
WO2019075468A1 (fr) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Procédés de traitement de tumeur
WO2019090156A1 (fr) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalisation de la charge de mutation tumorale
AU2018367925A1 (en) * 2017-11-17 2020-07-02 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
EP3622522A1 (fr) 2017-12-01 2020-03-18 Illumina, Inc. Procédés et systèmes de détermination de clonalité par mutation somatique
US20210054465A1 (en) * 2018-05-03 2021-02-25 Roche Sequencing Solutions, Inc. Surrogate marker and method for tumor mutation burden measurement
KR20210006405A (ko) * 2018-05-04 2021-01-18 메르크 파텐트 게엠베하 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
AU2019310041B2 (en) 2018-07-23 2025-11-20 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020021119A1 (fr) 2018-07-27 2020-01-30 F. Hoffmann-La Roche Ag Procédé de surveillance de l'efficacité d'immunothérapie de patients atteints d'un cancer
EP3845236A4 (fr) * 2018-08-29 2022-07-27 Tokyo Metropolitan Institute of Medical Science Agent antitumoral ciblant un substrat de tyrosine kinase régulée par hgf (hgs)
SG11202101400UA (en) 2018-08-31 2021-03-30 Guardant Health Inc Microsatellite instability detection in cell-free dna
EP3880246A4 (fr) 2018-11-15 2022-08-10 Personal Genome Diagnostics Inc. Procédé d'amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie
CN113194995A (zh) * 2018-12-12 2021-07-30 免疫医疗有限责任公司 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
WO2020252456A1 (fr) 2019-06-14 2020-12-17 The Trustees Of Columbia University In The City Of New York Inhibiteurs de nt5c2 pour le traitement de la leucémie lymphoblastique aiguë résistante à la chimiothérapie
EP4051314A4 (fr) * 2019-11-01 2023-12-06 Memorial Sloan Kettering Cancer Center Divergence de séquences de hla de classe i et cancérothérapie
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
CN115885050A (zh) 2020-04-28 2023-03-31 基因泰克公司 用于非小细胞肺癌免疫疗法的方法和组合物
CN116529835A (zh) * 2020-06-01 2023-08-01 Gmdx私人有限公司 预测癌症进展的方法
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
CA3200667A1 (fr) * 2020-11-06 2022-05-12 The General Hospital Corporation Procedes pour caracteriser des echantillons biologiques
WO2022235482A1 (fr) * 2021-05-03 2022-11-10 Rutgers, The State University Of New Jersey Immunothérapie pour une maladie intestinale inflammatoire et/ou un cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN122003713A (zh) 2023-04-12 2026-05-08 西奈山伊坎医学院 用于选择个性化新抗原疫苗的计算方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
NZ602892A (en) * 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
KR102095670B1 (ko) * 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
WO2013130748A1 (fr) * 2012-02-29 2013-09-06 The Regents Of The University Of Michigan Marqueurs du cancer de la prostate et leurs utilisations
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
AU2013323368B2 (en) * 2012-09-28 2019-03-21 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
SG10201805674YA (en) * 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
EP4098278A1 (fr) * 2014-11-13 2022-12-07 The Johns Hopkins University Blocage de point de contrôle et instabilité des microsatellites
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Also Published As

Publication number Publication date
JP2024125234A (ja) 2024-09-13
JP7173733B2 (ja) 2022-11-16
AU2015349644B2 (en) 2021-08-19
EP4393546A2 (fr) 2024-07-03
US12485162B2 (en) 2025-12-02
US20180291074A1 (en) 2018-10-11
JP2018502828A (ja) 2018-02-01
JP2023055625A (ja) 2023-04-18
CA2968059A1 (fr) 2016-05-26
CN107206064B (zh) 2021-12-21
CN114672559A (zh) 2022-06-28
EP3220950A4 (fr) 2018-08-29
CN107206064A (zh) 2017-09-26
AU2024278364A1 (en) 2025-02-13
AU2015349644A1 (en) 2017-06-15
EP3220950A2 (fr) 2017-09-27
HK1244440A1 (zh) 2018-08-10
US10993998B2 (en) 2021-05-04
JP2020196732A (ja) 2020-12-10
US20210308241A1 (en) 2021-10-07
WO2016081947A4 (fr) 2016-09-09
JP7550193B2 (ja) 2024-09-19
WO2016081947A3 (fr) 2016-07-07
EP4393546A3 (fr) 2024-12-11
WO2016081947A2 (fr) 2016-05-26
US20200040049A1 (en) 2020-02-06
AU2021215099A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
IL269810A (en) Combinatorial cancer immunotherapy
EP3624810A4 (fr) Immunothérapie anticancéreuse nano-activée
SG11201605432RA (en) Determinants of cancer response to immunotherapy
EP3402517A4 (fr) Immunothérapie du cancer
HUE053145T2 (hu) Kombinált tumor immunterápia
IL246978A0 (en) Novel pharmaceutical formulations
PL3283527T3 (pl) Leczenie skojarzone nowotworów
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
DK3204417T3 (da) Cd73-blokering
LT3097119T (lt) Žmogaus antikūnai prieš pd-1
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
EP3220950A4 (fr) Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
HUE059694T2 (hu) Készítmény rák kezelésére
EP3330034A4 (fr) Procédé d'assemblage par friction
IL247300A0 (en) Biomarker directed multi-target immunotherapy
EP3357485A4 (fr) Cosmétique d'écran solaire
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
IL248223A0 (en) Vaccine compositions
EP3127914C0 (fr) Dérivés d'adrénomédulline à action prolongée
DK3201559T3 (da) Patronhylster
EP3310915A4 (fr) Immunothérapie tumorale
PL3390450T3 (pl) Humanizowane przeciwciało anty-cd28 formułowane do podawania ludziom
EP3277701A4 (fr) Synthèse de désosamines
IL258408B (en) Improved synthesis of honokiol
DK3253407T3 (da) Brug af hla-b27-homodimere til kræftbehandling